



SEP 15 2005

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 Of 4

Complete if Known

Application Number	10/764,371
Filing Date	January 23, 2004
First Named Inventor	Lippa, et al
Art Unit	1626
Examiner Name	Taofiq Solola

Attorney Docket Number 2370-006-06

U.S. PATENT DOCUMENTS

Exam. Initials	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
YD	AA	US- 6,245,911	06/12/01	Imai, et al	Issued
	AB	US-6,204,284	03/20/01	Beer, et al	
	AC	US-6,194,000	02/27/01	Smith, et al	
	AD	US-6,121,261	09/19/00	Glatt, et al	
	AE	US-6,109,269	08/29/00	Rise, et al	
	AF	US- 5,985,864	11/16/99	Imai, et al	
	AG	US- 5,969,158	10/19/99	Briggs, et al	
	AH	US-5,911,992	06/15/99	Braswell, et al.	
	AI	US-5,762,925	06/09/98	Sagen	
	AJ	US- 5,574,052	11/12/96	Rose, et al	
	AK	US- 5,556,838	09/17/96	Mayer, et al	
	AL	US- 5,556,837	09/17/96	Nestler, et al	
	AM	US- 5,488,056	01/30/96	Bodick, et al	
	AN	US- 5,232,934	08/03/93	Downs	
	AO	US- 5,198,459	03/30/93	Imperato, et al	
	AP	US- 5,130,430	07/14/92	Shaw	
	AQ	US- 5,075,341	12/24/91	Mendelson, et al	
	AR	US- 5,039,680	08/13/91	Imperato, et al	
	AS	US- 4,591,598	05/27/86	Urbach, et al	
	AT	US- 4,521,431	06/04/85	Crookes	
	AU	US- 4,504,657	03/12/85	Bouzard, et al	
	AV	US- 4,435,419	05/06/84	Epstein, et al	
	AW	US- 4,336,268	06/22/82	Bruderer, et al	
	AX	US- 4,231,935	11/04/80	Fanshawe, et al	
	AY	US- 4,196,120	04/01/80	Fanshawe, et al	
	AZ	US- 4,131,611	12/26/78	Fanshawe, et al	
	BA	US- 4,118,417	10/03/78	Epstein	
	BB	US- 4,118,393	10/03/78	Fanshawe, et al	
	BC	US- 4,088,652	05/09/78	Fanshawe, et al	
	BD	US- 4,022,652	05/10/77	Hirano, et al	
	BE	US-3,892,722	07/01/75	Hoffman, et al	
	BF	US-6,372,919	04/16/02	Lippa, et al	
	BG	US-6,569,887	05/27/03	Lippa, et al	
	BH	US-6,716,868	04/06/04	Lippa, et al	
	BI	USSN 10/764,373 2004-0157870	08/12/04	Lippa, et al	
	BJ	USSN 10/764,375 2004-0157908	08/12/04	Lippa, et al	
	BK	USSN 10/702,397 2004-0102638	05/27/04	Russell, et al	
	BL	USSN 10/621,435 2004-0127541	07/01/04	Codd, et al	
	BM	USSN 10/466,457 2004-0132797	07/08/04	Lippa, et al.	

FOREIGN PATENT DOCUMENTS						
Exam. Initials	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
YD	BN	BE 858,683	12/30/82	BE (in French w/English Abstract)		Published
↓	BO	BE 893,707	12/30/82	BE (in French w/English Abstract)		Published
Examiner Signature	T. A. Solola		Date Considered	11-7-05		

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

3

Of

4

Complete If Known	
Application Number	
Filing Date	January 23, 2004
First Named Inventor	Lippa
Art Unit	1626
Examiner Name	Taofiq Solola
Attorney Docket Number	2370-006

Sheet	3	Of 4

NON PATENT LITERATURE DOCUMENTS

Exam. Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
10	BP	BALDESSARINI, R. <u>Drugs and The Treatment of Psychiatric Disorders</u> . Goodman & Gilman's The Pharmacological Basis of Therapeutics 9 th Edition. Hardman et al. eds. 1996. p. 399 and Ch 18:431-459, McGraw-Hill, New York ✓	
	BQ	BLUM, et al., <u>Dopamine D2 Receptor Gene Variants: Association and Linkage Studies In Impulsive-Addictive-Compulsive Behavior</u> . Pharmacogenetics 5:121-141, 1996. ✓	
	BR	BRAY, G. <u>A Concise Review On The Therapeutics of Obesity</u> . Nutrition 16:953-960, 2000. ✓	
	BS	CROWN, W. <u>Economic Outcomes Associated With Tricyclic Antidepressant And Selective Serotonin Reuptake Inhibitor Treatments For Depression</u> . Acta Psychiatr. Supp. 2000; 403:62-6. ✓	
	BT	D'AQUILA, et al, <u>The Role Of Dopoamine In The Mechanism of Action of Antidepressant Drugs</u> . Eur. J. Pharmacol. 405:365-373, 2000. ✓	
	BU	EPSTEIN, et al., <u>1-ARYL-3-AZABICYCLO[3.1.0]HEXANES. A New Series of Non-Narcotic Analgesic Agents</u> . J. Med. Chem. 24(5):481-90, 1981. ✓	
	BV	EPSTEIN, et al., <u>Bicifadine: Non-Narcotic Analgesic Activity of 1-ARYL-3-AZABICYCLO[3.1.0]HEXANES</u> . NIDA Res. Monogr. 41:93-98, 1982. ✓	
	BW	FRAZER, A. <u>Norepinephrine Involvement In Antidepressant Action</u> . J. Clin. Psychiatry. 61(10):25-30, 2000. ✓	
	BX	FREDMAN, et al., <u>Partial Response, Nonresponse, and Relapse With Selective Serotonin Reuptake Inhibitors In Major Depression: A Survey of Current "Next-Step" Practices</u> . J. Clin. Psychiatry 61(6):403-8, 2000. ✓	
	BY	Hackh's Chemical Dictionary, 4 th Edition, 1969, Julius Grant, ed., McGraw-Hill Book Company, New York, pp. 474-75 ✓	
	BZ	Harrison's Principles of Internal Medicine 2485-2503 (Fauci, et al., eds., 14 th ed. 1998) ✓	
	CA	HITRI, et al., <u>Molecular, Functional and Bichemical Characteristics of The Dopamine Transporter: Regional Differences and Clinical Relevance</u> . J. Clin. Pharmacol. 17:1-22, 1994. ✓	
	CB	HOFFMAN, et al., <u>Localization and Dynamic Regulation of Biogenic Amine Transporters In The Mammalian Central Nervous System</u> . Front. in Neuroendocrinol. 19(3): 187-213, 1998. ✓	

NON-PATENT LITERATURE DOCUMENTS			
Exam. Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
Y0	CC	KIYATKIN, E. <u>Dopamine Mechanisms of Cocaine Addiction</u> . Int. J. Neurosci. 78:75-101, 1994. ✓	
	CD	KREEK, M. <u>Cocaine, Dopamine and The Endogenous Opiod System</u> . J. Addict. Dis. 15:73-96, 1996. ✓	
	CE	LEONHARDT, et al., <u>New Approaches In The Pharmacological Treatment of Obesity</u> . Eur. J. Nutr. 38:1-13, 1999. ✓	
	CF	MEYERSON, et al., <u>Allosteric Interation Between The Site Labeled by ³Himipramine and The Serotonin Transporter In Human Platelets</u> . J. Neurochem. 48(2):560-65, 1987. ✓	
	CG	NAGATSU, et al., <u>Changes In Cytokines And Neurotrophins In Parkinson's Disease</u> . J. Neural. Transm. Suppl. 60:277-290, 2000. ✓	
	CH	NOBLE, E. <u>Polymorphisms of The D2 Dopamine Receptor Gene and Alcoholism and Other Substance Use Disorders</u> . Alcohol. Supp. 2:35-43, 1994. ✓	
	CI	PORTER, et al., <u>Single Dose Comparison of Bicifadine, Codeine, and Placebo in Postoperative Pain</u> . Current Therapeutic Research. 30(3):156-160, August 1981. ✓	
	CJ	SCATES, et al., <u>Reboxetine: A Selective Norepinephrine Reuptake Inhibitor For The Treatment Of Depression</u> . Ann. Pharmacother. 34(11):1302-12, 2000. ✓	
	CK	SIMON, et al., <u>TCAs or SSRIs As Initial Therapy For Depression?</u> J. of Family Practice, 48:845-46, 1999. ✓	
	CL	STACY, et al., <u>Treatment Options for Early Parkinson's Disease</u> . Am. Fam. Phys. 53:1281-87, 1996. ✓	
	CM	SULLIVAN, et al., <u>Mechanisms of Appetite Modulation By Drugs</u> . Federation Proceedings, Vol. 44, No. 1, Part 1, pp. 139-144, 1985. ✓	
	CN	WANG, et al., <u>The Oral Analgesic Efficacy of Bicifadine Hydrochloride In Postoperative Pain</u> . J. Clin. Pharmacol. 22(4):160-164, April 1982. ✓	
	CO	WONG, et al., <u>Reboxetine: A PharmacologicallyPotent, Selective, and Specific Norepinephrine Reuptake Inhibitor</u> . Biol. Psychiatry. 47(9):818-29, 2000. ✓	

Examiner Signature	T. A. Solo (a)	Date Considered	11-7-05
--------------------	----------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.